Brought to you by 
Before acquisition by Celgene, Acetylon spins out some HDAC inhibitor assets into Regenacy
14 Jan 2021
Executive Summary
Prior to its previously announced acquisition by Celgene, private biotech Acetylon Pharmaceuticals Inc. is divesting certain assets outside of Celgene’s areas of focus into a new company, Regenacy Pharmaceuticals LLC, which will have exclusive worldwide rights to these select Acetylon programs and related patents.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Acquisition
- Divestiture/Spin-Out
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Before acquisition by Celgene, Acetylon spins out some HDAC inhibitor assets into Regenacy
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice